Dr. Steven A. Phillips, MD
Pediatrics (Pediatrics Physician)
315 Martin Luther King Jr Way
Tacoma, WA 98405
Who else practices at this address →
Pierce County includes primary care (20% of residents) and dental (11% of residents) and mental health (11% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2006
Licensed in Washington since 2005, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatrics Physician primary
WA license MD00045897 (first issued 2005; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $4,080 in total to this clinician.
| UCB Biosciences Inc. | $4,080 |
|---|
| Compensation for services other than consulting (speaking, faculty) | $4,080 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| UCB Biosciences Inc. Jul 18, 2025 | Compensation for services other than consulting (speaking, faculty) Fintepla · Neurology | $4,080 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $127,247 in research payments for these studies, mostly to the institutions running them.
- Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
Sk Life Science, Inc. · Completed · NCT05067634 - A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
H. Lundbeck A S - A study of soticlestat as an add-on therapy in children and adults with dravet syndrome or lennox-gastaut syndrome
Takeda Pharmaceuticals U.S.A., Inc. - Alogabat study in AS children and adolescents
Genentech, Inc. - A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
H. Lundbeck A S - Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder
Acadia Pharmaceuticals Inc · Terminated · NCT05555615 - A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
H. Lundbeck A S
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.